Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675959 | 0.91 | GSK3B (0.48) | GSK3BHDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL16675941 | 0.91 | GSK3B (0.48) | GSK3BHDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL16675937 | 0.81 | GSK3B (0.51) | GSK3BHDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL16675947 | 0.79 | GSK3B (0.44) | GSK3BMAPK1DYRK1A | |
| SCHEMBL16682168 | 0.78 | P2RX7 (0.37) | GSK3BMAPK1 | |
| SCHEMBL19976888 | 0.77 | GSK3B (0.51) | GSK3BHDAC6TRPA1HDAC1HDAC2 | |
| SCHEMBL16675951 | 0.77 | GSK3B (0.48) | GSK3BHDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL16769264 | 0.76 | HDAC6 (0.45) | GSK3BHDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL16752836 | 0.76 | HDAC6 (0.45) | GSK3BHDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL16752833 | 0.76 | HDAC6 (0.45) | GSK3BHDAC6HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | GSK3B 4407/4885HDAC6 306/4885TRPA1 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.